Detalhe da pesquisa
1.
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology
; 129(3): 295-307, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597713
2.
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction.
Mol Pharm
; 17(2): 695-709, 2020 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876425
3.
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Ophthalmology
; 126(8): 1141-1154, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30946888
4.
Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.
Nucleic Acids Res
; 45(13): 7602-7614, 2017 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28641400
6.
Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections.
Am J Ophthalmol
; 258: 158-172, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453472
7.
International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.
Clin Transl Sci
; 16(5): 723-741, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36651217
8.
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration.
J Clin Pharmacol
; 63(11): 1210-1220, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37291950
9.
In-vitro characterization of ranibizumab release from the Port Delivery System.
J Control Release
; 345: 101-107, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248647
10.
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration.
Ophthalmol Ther
; 11(5): 1705-1717, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759124
11.
Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: Promise to reality.
Clin Transl Sci
; 15(12): 2785-2795, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129129
12.
Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Am J Ophthalmol
; 232: 49-57, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214452
13.
Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.
MAbs
; 9(8): 1297-1305, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854082
14.
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.
AAPS J
; 18(3): 635-46, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26912181
15.
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
AAPS J
; 18(4): 861-75, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27029797
16.
Will patient-centric sampling become the norm for clinical trials after COVID-19?
Nat Med
; 26(12): 1810, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33230340
17.
Dynamic swelling behavior of interpenetrating polymer networks in response to temperature and pH.
J Appl Polym Sci
; 132(24)2015 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26405349
18.
A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.
J Pharm Sci
; 104(12): 4409-4416, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26344409